Thomas Ulich, chief scientific officer of InVivo Therapeutics (NASDAQ: [[ticker:NVIV]]) since 2015, is out of a job. The Cambridge, MA, biotech is eliminating 13 positions, including Ulich’s, as part of a corporate restructuring, according to regulatory filings. InVivo says the restructuring will help the company focus its resources on its experimental treatment for spinal cord injury.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
